Year: 2026
Type: preprint
Abstract: KRAS mutations are enriched in resistant myeloid neoplasms and are associated with poor prognosis. The lack of distinct surface markers makes it difficult to distinguish RAS-mutant leukemic stem and progenitor cells from normal counterparts and define their functional properties within mixed human bone marrow populations. Thus, Genotyping of Transcriptomes was performed across a spectrum of myeloid malignancies and showed that KRAS mutant cells formed a distinct inflammatory, stem/progenitor-like population characterized by CD83 overexpression. CD83+ mutant cells displayed impaired differentiation, whereas CD83 blockade in a novel transplantable KrasG12D mouse model reduced leukemogenic potential and prolonged survival. Selective KRASG12D inhibition in patient samples and in vivo promoted erythroid differentiation, reduced monocytosis and tumor burden, and reversed inflammatory cytokine production. The transplantable KrasG12D model recapitulated human disease, including extramedullary granulocytic tumors, and responded to treatment with a selective KRASG12D inhibitor. These findings identify CD83 as a novel therapeutic target across KRASG12D-mutant myeloid neoplasms.
Source: Research Square
Authors: Amit Verma, Leah Kravets, Mirca Saurty-Seerunghen, Divij Verma, Srabani Sahu, Rahul Sanawar, Swathi-Rao Narayanagari, Shanisha Gordon, Jinghang Zhang, Rongbao Zhao, Milagros Carbajal, Srinivas Aluri, Ariel Fromowitz, Olivia Sakaguchi, Chi-Lam Poon, Ritesh Agarwal, Jingli Wang, Amittha Wickrema, Hussein Abbas, Mendel Goldfinger, Aditi Shastri, Ulrich Steidl, Lindsay LaFave, Marina Konopleva, Anna Nam
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7236690756
